Date: 2016-10-06
Type of information: Production agreement
Compound: atexakin alfa
Company: PX’Therapeutics, a subsidiary of the Aguettant group (France) Relief Therapeutics (Switzerland)
Therapeutic area: Metabolic diseases - Neurological diseases
Type agreement: production manufacturing
Action mechanism: protein. Atexakin alfa is a low dose interleukin-6 (atexakin alfa) for the treatment of peripheral diabetic neuropathy (already in Phase II). Atexakin alfa is the subject of an exclusive worldwide development and commercialization agreement with a Merck Serono, and has been the subject of multiple clinical trials and representing a major capital investment. Based on its unique mechanism of action, atexakin alfa could become the first regenerative therapeutic for peripheral neuropathy.
Disease: peripheral diabetic neuropathy
Details: * On October 6, 2016, PX’Therapeutics, a subsidiary of the Aguettant group, a company that specializes in the customer-tailored development of recombinant proteins, and Relief Therapeutics, a biotechnology company dedicated to the clinical development of innovative molecules for the treatment of certain diabetes-related complications, respiratory disorders and rare diseases, have announced a strategic collaboration agreement for the production of atexakin alfa, a low-dose formulation of the recombinant human protein interleukin-6. This candidate aims to fulfill an unmet medical need in peripheral diabetic neuropathy by regenerating damaged nerve fibers, stimulating remyelination and reducing neuropathic symptoms. No existing marketed therapies for peripheral neuropathy are able to regenerate damaged peripheral nerves. As such, therefore, atexakin alfa could become the first truly disease-modifying drug for this condition. In this project, PX’Therapeutics will develop an optimized production process for recombinant interleukin 6, a 185-amino acids cytokine, in CHO cells. PX’Therapeutics will also produce, in accordance with current Good Manufacturing Practices (cGMP) guidelines, protein batches that will be used for clinical trials.
Financial terms:
Latest news:
